論文 - 詳細
| RRC ID | 66206 |
|---|---|
| 著者 | Le VVH, Olivera C, Spagnuolo J, Davies IG, Rakonjac J. |
| タイトル | In vitro synergy between sodium deoxycholate and furazolidone against enterobacteria. |
| ジャーナル | BMC Microbiol |
| Abstract |
BACKGROUND:Antimicrobial combinations have been proven as a promising approach in the confrontation with multi-drug resistant bacterial pathogens. In the present study, we identify and characterize a synergistic interaction of broad-spectrum nitroreductase-activated prodrugs 5-nitrofurans, with a secondary bile salt, Sodium Deoxycholate (DOC) in growth inhibition and killing of enterobacteria. RESULTS:Using checkerboard assay, we show that combination of nitrofuran furazolidone (FZ) and DOC generates a profound synergistic effect on growth inhibition in several enterobacterial species including Escherichia coli, Salmonella enterica, Citrobacter gillenii and Klebsiella pneumoniae. The Fractional Inhibitory Concentration Index (FICI) for DOC-FZ synergy ranges from 0.125 to 0.35 that remains unchanged in an ampicillin-resistant E. coli strain containing a β-lactamase-producing plasmid. Findings from the time-kill assay further highlight the synergy with respect to bacterial killing in E. coli and Salmonella. We further characterize the mechanism of synergy in E. coli K12, showing that disruption of the tolC or acrA genes that encode components of multidrug efflux pumps causes, respectively, a complete or partial loss, of the DOC-FZ synergy. This finding indicates the key role of TolC-associated efflux pumps in the DOC-FZ synergy. Overexpression of Nitric Oxide-detoxifying enzyme Hmp results in a three-fold increase in FICI for DOC-FZ interaction, suggesting a role of nitric oxide in the synergy. We further demonstrate that DOC-FZ synergy is largely independent of NfsA and NfsB, the two major activation enzymes of the nitrofuran prodrugs. CONCLUSIONS:This study is to our knowledge the first report of nitrofuran-deoxycholate synergy against Gram-negative bacteria, offering potential applications in antimicrobial therapeutics. The mechanism of DOC-FZ synergy involves FZ-mediated inhibition of TolC-associated efflux pumps that normally remove DOC from bacterial cells. One possible route contributing to that effect is via FZ-mediated nitric oxide production. |
| 巻・号 | 20(1) |
| ページ | 5 |
| 公開日 | 2020-1-6 |
| DOI | 10.1186/s12866-019-1668-3 |
| PII | 10.1186/s12866-019-1668-3 |
| PMID | 31906851 |
| PMC | PMC6945529 |
| MeSH | Bacterial Outer Membrane Proteins / genetics Citrobacter / drug effects Citrobacter / growth & development Deoxycholic Acid / pharmacology* Drug Resistance, Bacterial / drug effects* Drug Synergism Enterobacteriaceae / drug effects Enterobacteriaceae / growth & development* Escherichia coli / drug effects Escherichia coli / growth & development Escherichia coli Proteins / genetics Furazolidone / pharmacology* Gene Expression Regulation, Bacterial / drug effects Klebsiella pneumoniae / drug effects Klebsiella pneumoniae / growth & development Lipoproteins / genetics Membrane Transport Proteins / genetics Microbial Viability / drug effects Prodrugs / pharmacology Salmonella enterica / drug effects Salmonella enterica / growth & development |
| IF | 2.989 |
| リソース情報 | |
| 原核生物(大腸菌) | ASKA collection |